Could diabetes drugs help kidney patients avoid anemia?
NCT ID NCT07063316
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether SGLT2 inhibitors, a type of diabetes drug, can help prevent or manage anemia in people with chronic kidney disease. Researchers will analyze data from 15,000 patients in Japan to see how these drugs affect anemia rates, treatments, and costs. The goal is to better understand the link between SGLT2 inhibitors and anemia in this population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SGLT2 inhibitor
- What this could lead to
- If successful, this could help doctors understand whether SGLT2 inhibitors help prevent or manage anemia in kidney disease patients.
- What could go wrong
- This is an observational study, not a treatment trial, so it cannot prove cause and effect. Results may not apply outside Japan.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nippon Boehringer Ingelheim Co ., Ltd.
Tokyo, 1416017, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk